Opinion paperOvercoming barriers to diabetic polyneuropathy management in primary care
Introduction
An estimated 15 million people in the U.S. and more than 200 million across the globe are likely to develop nerve damage associated with diabetes called diabetic polyneuropathy (DPN).1 DPN accounts for nearly one-third of all diabetes related expenditures in the U.S., which are estimated at close to $250 billion per year.2 While DPN is not curable, progression can be slowed through improved glycemic control and long term impact may be reduced through effective treatment of symptoms.3, 4
Most patients with DPN experience sensations of pain, numbness, tingling, electronic shock, and/or pins and needles (paraesthesia) that initiate in the toes and feet and spread to the upper limbs in a “stocking and “glove pattern.1, 5 The burden associated with these symptoms has a dramatic negative impact on patient quality of life, health status and functioning.6 While pharmacologic and other interventions are available to treat these symptoms, there is growing evidence that DPN is underdiagnosed and undertreated in primary care settings.7, 8 In this article, we highlight three factors that contribute to suboptimal management of DPN symptoms and encourage the development of novel system-level strategies to re-prioritize DPN symptom management within the broader context of diabetes management.
- 1)
Diagnostic complexity: There is no single test a provider can order to definitively diagnose DPN.1,3 Instead, physicians must be guided by a combination of physical exam and patient symptom reports. Nerve conduction studies rarely change the clinical management of patients with suspected DPN, and likely should be reserved for those with atypical features (asymmetry, non-length dependence, motor predominance, acute/subacute presentation).9, 10 Surprisingly, neuroimaging studies are frequently performed, but also are unlikely to change management strategies.9, 10, 11 Current guidelines recommend serologic testing with a fasting glucose, glucose tolerance test, serum protein electrophoresis with immunofixation, and B12 for patients with polyneuropathy, but whether any serologic testing in those with known diabetes is needed is unknown.3, 12 Clinical guidelines recommend screening at diagnosis and annually thereafter;3 though DPN may also appear among those with prediabetes.1, 13
Screening tests (e.g., 10 g Semmes-Weinstein monofilament test) may help primary care physicians screen for neuropathy.3 Yet, recent studies suggest that the monofilament test, which is considered the cornerstone for assessing the quality of diabetes foot care in many settings, exhibits considerable variability in sensitivity and specificity.14, 15 Given the limitations of this and other screening tests, validated questionnaires and examination tools are likely the best way to screen for DPN.5
Despite the importance of frequent patient-provider communication,1, 3, 5 there are considerable barriers to effective DPN symptom assessment in practice, such as low health literacy, language barriers and patients’ reluctance to discuss pain symptoms.8, 16 In addition, the increasingly time constrained primary care visit may contribute to communication barriers and resulting diagnostic errors.17, 18, 19 For conditions like DPN, missed opportunities for clinical recognition during primary care visits can have devastating downstream consequences.
- 2)
Heterogeneity of treatment response: Once recognized, a major challenge to effective treatment of DPN symptoms is the lack of robust clinical evidence regarding which treatment options are likely to work best for which patients.1, 3, 5, 20 There is a wide range of efficacious medications, including tricyclic antidepressants, voltage gated calcium channel ligand agonists, and serotonin norepinephrine reuptake inhibitors.1, 3, 5, 20 However, there is considerable variation in patient tolerability of side effects and costs, as well as a lack of evidence regarding the comparative efficacy of these therapies over the short and long term.3, 20
As a consequence, effective treatment strategies often require intensive step-wise up-titration and medication changes to reach a dose that optimally balances medication benefit and burden.1, 3, 5, 20 Recent studies suggest that combination therapy may be more effective than monotherapy for patients who do not respond to first line treatment.21 Moreover, the identification of specific genetic markers associated with DPN progression suggest that personalized pharmacotherapies may be forthcoming.1, 5
While intensive glycemic control has been associated with a lower incidence of DPN, there is insufficient evidence to support it as a viable intervention for symptom management.5 Recently, a Veterans Administration study demonstrated that intensive cognitive behavioral therapy may be effective as an adjunct to traditional pharmacotherapy for some patients, though more studies are needed to confirm this finding.22 Importantly, the generalizability of these and other clinical trial findings to real world populations is unknown and patient and provider knowledge of available treatments is limited; thus hindering progress toward rational decision-making.7, 8
- 3)
System-level barriers: Perhaps the biggest barrier to optimizing DPN management lies in how health systems prioritize DPN symptoms in the larger context of diabetes management. The reality for patients and providers alike is that provider performance and subsequent payment are linked to tangible, objective measures of diabetes management and control (e.g., A1c), not symptoms. Yet, glycemic control, undeniably an important target for care intervention,3 is a poor indicator of pain interference, quality of life, functioning and other patient-valued outcomes.17 Overcoming the unique challenges posed by DPN management will require a paradigmatic shift at the health system level toward management strategies that prioritize patient-valued outcomes at least as much as clinical markers.
Retinopathy screening, which has been shown to be cost-effective in preventing sight loss for diabetes patients, may represent a strong example of what could be possible with DPN.23 Like retinopathy, DPN screening can be easily conducted using exam or validated questionnaire and, therefore, monitored and linked to reimbursement or financial incentives. However, unlike retinopathy, the next step of assessment of neuropathic pain and treatment decisions are harder to identify in the medical record in an automated way. Identifying methods for systematizing the process of pain assessment and automating data collection are critical in the development of effective and sustainable strategies for promoting high quality DPN management in primacy care practice.
Section snippets
Toward for a patient-centered system-level approach
There is mounting evidence that a one size fits all approach to diabetes management may limit the ability of physicians to focus on the needs of individual patients.17, 24 For example, many patients with DPN symptoms may benefit more from an immediate focus on current symptom management than on efforts directed towards long-term prevention. Such a patient-centered approach will require new and innovative strategies to align patient, provider, and health system priorities toward doing what is
Funding
For this work was supported through a Patient-Centered Outcomes Research Institute (PCORI) Assessment of Prevention, Diagnosis, and Treatment Options Program Award [CE-1304–7250] and the Division of Diabetes Translation, Centers for Disease Control and Prevention [U58 DP002641]. Dr. Grant is supported by NIDDK (R01DK099108), NHLBI (R01 HL117939) and PCORI (SC14-1403–11992).
Disclaimer
All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee
Conflict of interest disclosure statement
This statement accompanies the article Overcoming barriers to diabetic polyneuropathy management in primary care. Authored by Alyce S. Adams and co-authored by Brian Callaghan and Richard W. Grant and submitted to Healthcare as an Article Type. Authors collectively affirm that this manuscript represents original work that has not been published and is not being considered for publication elsewhere.We also affirm that all authors listed contributed significantly to the project and manuscript.
Acknowledgements
The authors with to thank Dr. Rick Dlott, Medical Director for Population Care at The Permanente Medical Group for comments on an earlier draft of this manuscript.
References (33)
- et al.
Diabetic neuropathy: clinical manifestations and current treatments
Lancet Neurol
(2012) The clinical use of the 10g monofilament and its limitations: a review
Diabetes Res Clin Pr
(2010)- et al.
Establishing visit priorities for complex patients: a summary of the literature and conceptual model to guide innovative interventions
Health Care: J Deliv Sci Innov Health (Amst)
(2013) - et al.
Diabetic retinopathy screening: a systematic review of the economic evidence
Diabet Med
(2010) - et al.
Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy
Clin Neurol Neurosurg
(2006) - et al.
Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy
Diabetes Metab Res Rev
(2012) Economic costs of diabetes in the U.S. in 2012
Diabetes Care
(2013)Standards of medical care in diabetes—2015
Diabetes Care
(2015)The effect of intensive diabetes therapy on the development and progression of neuropathy
Ann Intern Med
(1995)- et al.
Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey
Diabetes, Metab Syndr Obes: Targets Ther
(2013)
Suboptimal treatment of diabetic peripheral neuropathic pain in the United States
Pain Med
The need for improved management of painful neuropathy in primary care
Pain Res Manag
Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy
JAMA Neurol
Headaches and neuroimaging: high utilization and costs despite guidelines
JAMA Intern Med
Tests and expenditures in the initial evaluation of peripheral neuropathy
Arch Intern Med
American academy of neurology; american association of neuromuscular and electrodiagnostic. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the american academy of neurology, the american association of neuromuscular and electrodiagnostic medicine, and the american academy of physical medicine and rehabilitation. medicine; american academy of physical medicine and rehabilitation
Neurology
Cited by (5)
Stimulating Results Signal a New Treatment Option for People Living With Painful Diabetic Neuropathy
2023, Journal of Diabetes Science and TechnologyClinical use of neurotropic B vitamins in diseases of the peripheral nervous system in Mexico and Central America
2022, Medicina Interna de MexicoDiabetes Distal Peripheral Neuropathy: Subtypes and Diagnostic and Screening Technologies
2022, Journal of Diabetes Science and TechnologyCannabis for peripheral neuropathy: The good, the bad, and the unknown
2018, Cleveland Clinic Journal of Medicine